⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S3 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma

Yun Bin Lee Joon Yeul Nam Eun Ju Cho Jeong‐Hoon Lee Su Jong Yu Hyo‐Cheol Kim Jin Chul Paeng Jung‐Hwan Yoon Yoon Jun Kim

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S3. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db64358752279c https://doi.org/10.1158/1078-0432.27033355

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024
2Supplementary Figure S2 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024
3Supplementary Figure S2 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024
4Supplementary Figure S1 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024
5Supplementary Figure S1 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024

Supplementary Figure S5 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024
Supplementary Figure S5 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024
Supplementary Figure S4 from A phase 1/2a trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma2024